Challenges and opportunities in gene therapy development
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
List view / Grid view
Articles
Monitoring the potency of cell therapies using bioelectronic assays
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
Millennia in the making: unlocking the medicinal value of CBD
Dr Sotirios Karathanasis discusses the history of cannabis as a treatment and delves into the process of turning plant-based medicines into clinically proven drugs.
How microfluidics can automate drug discovery and development
Researchers from the University of Minnesota have developed a 3D spherical microfluidic device. Here, Dr Ruitao Su explains how the new device can be used in drug discovery and development.
Five of the latest developments in 3D bioprinting
Drug Target Review brings you five of the most recent developments in three-dimensional (3D) bioprinting.
Healthcare demands drive domestic UK biotech investment
Dmytro Spilka explains why UK biotech companies are receiving increasing levels of investment and why this trend is likely to continue.
Airway-on-a-chip technology enables COVID-19 drug repurposing
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
ebook: Antibody Discovery – technology and techniques to boost development
The latest ebook from Sartorius takes an in-depth look at the technologies and techniques that have been integral to developing the antibody discovery workflow, featuring a host of expert articles, interviews and application notes.
New developments in the research field of immuno-oncology
The exciting potential of immunotherapy for cancer treatment continues its exploration and here, Drug Target Review investigates three of the latest pre-clinical developments in immuno-oncology research.
Protecting liposomes in COVID-19 mRNA vaccines could increase their stability
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
Targeting TNF to treat Dupuytren’s disease, frozen shoulder and POCD
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
Exploring the connection between COVID-19 and diabetes
Dr Brittany Busse discusses why COVID-19 can influence the onset of diabetes and how this could shape the development of therapeutics.
COVID-19, broad-spectrum therapeutics and the magic blanket paradigm
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
Expanding accessible chemical space through automated high-throughput experimentation
Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.
How RNA therapeutics can be used to treat retinitis pigmentosa
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.